Outcomes of Patients with Refractory/Relapsed Diffuse Large B-Cell Lymphoma Who Progress After Autologous Stem Cell Transplantation in the Rituximab Era.

被引：0
|
作者：
Nagle, Sarah J. [1 ]
Woo, Kaitlin [2 ]
Mick, Rosemarie [2 ]
Schuster, Stephen J. [1 ]
Nasta, Sunita D. [1 ]
Stadtmauer, Edward A. [1 ]
Svoboda, Jakub [1 ]
机构：
[1] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.2689.2689
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2689
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PREVIOUS RITUXIMAB EXPOSURE DOES NOT AFFECT CLINICAL OUTCOMES OF HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Park, S.
    Yoon, D. H.
    Kim, S.
    Park, C.
    Huh, J.
    Suh, C.
    HAEMATOLOGICA, 2012, 97 : 675 - 675
  • [22] Association of prior rituximab exposure among patients undergoing autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma with inferior outcomes in males compared with females.
    Lazaryan, Aleksandr
    Copelan, Edward Alan
    Bejanyan, Nelli
    Dean, Robert M.
    Sobecks, Ronald M.
    Hill, Brian Thomas
    Pohlman, Brad L.
    Kalaycio, Matt E.
    Bolwell, Brian James
    Sweetenham, John W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma
    Zhang, Wei
    Jiao, Li
    Zhou, Dao-Bin
    Shen, Ti
    ONCOLOGY LETTERS, 2010, 1 (04) : 733 - 738
  • [24] The efficacy and safety of autologous stem cell transplantation in relapsed chemosensitive and chemoresistant patients with diffuse large B-cell lymphoma
    Armatys, A.
    Wieczorkiewicz-Kabut, A.
    Panz-Klapuch, M.
    Koclega, A.
    Kopinska, A. J.
    Kata, D.
    Wozniczka, K.
    Helbig, G.
    NEOPLASMA, 2020, 67 (06) : 1431 - 1436
  • [25] Outcomes of Cardiac Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Al-Juhaishi, Taha
    Abu Zeinah, Ghaith
    Al-Kindi, Sadeer
    BLOOD, 2020, 136
  • [26] Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma
    Joseph, Jacinth
    Ma, Junsheng
    Hennawy, Fady
    Abdulrazzaq, Mustafa Nooruldeen
    Saini, Neeraj
    Patel, Romil D.
    Hosing, Chitra M.
    Alousi, Amin M.
    Anderlini, Paolo
    Popat, Uday R.
    Qazilbash, Muzaffar H.
    Shpall, Elizabeth J.
    Srour, Samer
    Kebriaei, Partow
    Bashir, Qaiser
    Nastoupil, Loretta J.
    Westin, Jason R.
    Rondon, Gabriela
    Champlin, Richard E.
    Andersson, Borje S.
    Nieto, Yago
    Muzzafar, Tariq
    Ahmed, Sairah
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (05): : 404.e1 - 404.e5
  • [27] Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era
    Sesques, Pierre
    Bourcier, Jessie
    Golfier, Camille
    Lebras, Laure
    Nicolas-Virelizier, Emmanuelle
    Hacini, Maya
    Perrin, Marie Claire
    Voillat, Laurent
    Bachy, Emmanuel
    Traverse-Glehen, Alexandra
    Moreau, Anne
    Martin, Laurent
    Ramla, Selim
    Casasnovas, Olivier
    Le Gouill, Steven
    Salles, Gilles
    Ghesquieres, Herve
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (02) : 137 - 145
  • [28] Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party
    S P Robinson
    A Boumendil
    H Finel
    D Blaise
    X Poiré
    E Nicolas-Virelizier
    R Or
    R Malladi
    A Corby
    L Fornecker
    D Caballero
    D Pohlreich
    A Nagler
    C Thieblemont
    J Finke
    E Bachy
    L Vincent
    W Schroyens
    H Schouten
    P Dreger
    Bone Marrow Transplantation, 2016, 51 : 365 - 371
  • [29] Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party
    Robinson, S. P.
    Boumendil, A.
    Finel, H.
    Blaise, D.
    Poire, X.
    Nicolas-Virelizier, E.
    Or, R.
    Malladi, R.
    Corby, A.
    Fornecker, L.
    Caballero, D.
    Pohlreich, D.
    Nagler, A.
    Thieblemont, C.
    Finke, J.
    Bachy, E.
    Vincent, L.
    Schroyens, W.
    Schouten, H.
    Dreger, P.
    BONE MARROW TRANSPLANTATION, 2016, 51 (03) : 365 - 371
  • [30] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Kayoko Murayama
    Toru Kiguchi
    Koji Izutsu
    Yoshihiro Kameoka
    Michihiro Hidaka
    Harumi Kato
    Shinya Rai
    Junya Kuroda
    Kenichi Ishizawa
    Satoshi Ichikawa
    Kiyoshi Ando
    Michinori Ogura
    Koji Fukushima
    Yasuhito Terui
    Annals of Hematology, 2022, 101 : 979 - 989
12345